MAPT and Alzheimer disease: In APP/PS1/tau triple transgenic AD (3×Tg-AD) model mice, CIG can improve learning and memory impairment by reducing Aβ content and tau hyperphosphorylation and increasing neurotrophic factors in the brain (Yang C. et al., 2020).